搜尋結果
Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial Read more News archive
Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. 24256790 Our medicines are for the approved indication for which they are authorised in the local country or region. For more information, please visit our product page
Overview of Novo Nordisk pharmaceutical products within diabetes, obesity, haemophilia, human growth hormone and hormone replacement therapy.
For more than 100 years, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems, like our insulin pens. Our treatments today are benefiting millions of people living with diabetes, obesity, and rare blood and endocrine diseases.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in discovering and developing treatment for serious chronic disease, like diabetes and obesity.
1923-2023 Driving change for generations. Young people at Tingbjerg, Denmark. As Novo Nordisk turns 100, we renew our commitment to drive change for a healthy world today, and for generations to come. A life-saving discovery turns 100 years.
2024年10月14日 · Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
2024年3月5日 · Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW.
Product-related press releases will only be available upon request after three weeks of publication on our website in order to comply with applicable regulation. Stay updated. Be the first to read our company announcements and press releases. Sign up to Novo Nordisk News.
2021年11月18日 · Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform. Bagsværd, Denmark, 18 November 2021 – Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference (RNAi ...
